Medivir terminates the ADAM8 inhibitor project for pancreatic cancer

Medivir terminates the ADAM8 inhibitor project for pancreatic cancer

STOCKHOLM--()--Regulatory News:

Medivir AB (Nasdaq Stockholm: MVIR) today announces that it will terminate its ADAM8 inhibitor project for pancreatic cancer. The closure of the project follows a semi-annual review of the company's R&D project portfolio, which deprioritized the project based on data generated during the last six months. As a consequence the license agreement with Cancer Research Technology (CRT) for ADAM8 inhibitors and the collaboration with CRT and TransMIT GmbH will be terminated.

With the closure of this project, internal resources are transferred to the company's other oncology discovery projects. These projects are focused on the identification of new treatments for hepatocellular carcinoma, pancreatic cancer and other areas of high unmet medical need among cancer patients, and utilize Medivir's core technologies of protease inhibitor design and nucleoside/nucleotide science.

Medivir is required under the Securities Markets Act to make the information in this press release public.

The information was submitted for publication at 08.30 CET on 17 November 2015.

About Medivir

Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

This information was brought to you by Cision http://news.cision.com

Contacts

Medivir AB
Ola Burmark, CFO
mobile: +46 (0) 725 480 580
or
Richard Bethell, EVP Discovery Research
mobile: +46 (0) 727 043 211

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.